The counterfeit detective - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

KeywordLocation
About Search
The counterfeit detective
As counterfeiters become more cunning and technologically advanced, spotting their handiwork is increasingly difficult. Can surface analysis techniques be used to outwit them?


Pharmaceutical Technology Europe


We are a pharmaceutical tablet manufacturer that is increasingly concerned by counterfeit drugs. We have received tablets that we suspect are counterfeit, but examination of the bulk composition has shown no significant differences. Could surface analysis techniques be utilized to determine the difference between genuine products and copies?

The answer is yes if the route of manufacture is different. However, before going into specifics we should define counterfeit drugs, explain the background and why they are such a large problem.

The threat

Counterfeiting was first recognized by the World Health Organization in 1985 and the agency estimates that the sales of fraudulent drugs will reach $75 billion (€47.9 billion) by 2010.1 Currently, counterfeit pharmaceuticals are believed to account for 10% of the global supply chain and this percentage rises to 70% in some developing countries. Even in the US, a country renowned for having some of the most stringent regulations for the pharmaceutical industry, the sale of counterfeit drugs was estimated at $32 billion (€20.4 billion) in 2006.

While the direct effect on pharmaceutical company profits is important, the most concerning aspect is the health risks. In the best case scenario the counterfeit drug performs as the genuine article with no side-effects, in the worst case scenario the counterfeit drug results in death.

Currently, counterfeit drugs can be split into several categories:

  • products without active ingredients
  • products with incorrect quantities of active ingredients
  • products with the wrong ingredients
  • products with the correct quantities of active ingredients but with fake packaging
  • products with high levels of impurities and contaminants
  • copies of the original product.


Justine Bentley
Counterfeit drugs with the wrong chemical composition or contaminants can be investigated by a range of techniques such as nuclear magnetic resonance, near infrared spectrometry, thin layer chromatography, desorption electrostatic ionization, Raman spectroscopy, X-ray diffraction and liquid chromatography–mass spectrometry. However, those that contain the correct ingredients in the correct amounts (i.e., copies of the original) are more difficult to identify while potentially being as deadly as those with the incorrect ingredients.

Regarding the initial question, we need to understand why drugs with the correct ingredients in the correct amounts are a problem.

At first, these drugs may not appear to have the same health concerns as other types of counterfeit drugs, but it is not just the profits of pharmaceutical companies that suffer because of the practice of copying originals. Just because a drug contains the same ingredients as a genuine drug doesn't mean it will react in the same way or, more precisely, have the same effects on the person taking it. Drugs are specially designed to release APIs at set times if the composition is correct, but if the distribution of the counterfeit is different then it will produce undesired effects.


ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
When sourcing raw materials and non-GMP intermediates or other chemicals, where are the majority of your suppliers located?
In the United States
In Western Europe
In Central and Eastern Europe
In Japan
In India
In China
In the United States
18%
In Western Europe
19%
In Central and Eastern Europe
3%
In Japan
2%
In India
31%
In China
28%
View Results
Jim MillerOutsourcing OutlookJim Miller Time for a Model Upgrade
Patricia Van ArnumIngredients InsiderPatricia Van Arnum Navigating the Global Pharmaceutical Supply Chain
Faiz kermaniSpotlightFaiz Kermani Reinvigorating European R&D innovation
Faiz kermaniStatistical Solutions Lynn Torbeck%RSD: Friend or Foe?
Life After Big Pharma
PhRMA Details Its Proposal for Internet and Social-Media Standards
The Unregulated Regulator
Rx-360 Goals Get off the Ground
US and Europe At Risk from Substandard Medicines
FindPharma Custom Search
Source: Pharmaceutical Technology Europe,
Click here